Intra-arterial renal infusion of autologous mesenchymal stem cells for treatment of chronic kidney disease in cats: Phase I clinical trial.

ABSTRACT:

Background

There are no known treatments that halt or reverse chronic kidney disease (CKD) in cats. In rodent models, stem cell treatment has been associated with improvement in renal function parameters, especially when stem cells were delivered intra-arterially to the kidney. To date, only IV and intrarenal stem cell infusions have been studied in cats with CKD with no clinically relevant improvement noted.

Objective

To assess the safety and feasibility of intra-arterial delivery of autologous mesenchymal stem cells (MSC) in stromal vascular fraction (SVF) to the kidney in cats with CKD.

Animals

Five client-owned domestic cats with International Renal Interest Society stage III CKD.

Methods

Prospective cohort study (phase I clinical trial). Adipose tissue was

SUBMITTER: Thomson AL 

PROVIDER: S-EPMC6524114 | biostudies-literature | 2019 May

REPOSITORIES: biostudies-literature